search for


Optimal Target Low-density Lipoprotein Level for Reducing the Risk of Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
Korean J Clin Pharm 2023;33(4):270-277
Published online December 31, 2023
© 2023 Korean College of Clinical Pharmacy.

Min-Gyo Jang1, Yeung-Eun Son1, Hye Duck Choi2, Junwoo Kim3, Tae-Eun Kim1, and Kwang-Hee Shin1*

1College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Republic of Korea
2College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea
3Department of Family Medicine, Daegu Health College Hospital, Daegu 41422, Republic of Korea
Correspondence to: Kwang-Hee Shin, College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Republic of Korea
Tel: +82-53-950-8582, Fax: +82-53-950-8557, E-mail:

This work was presented in 26th Korean College of Clinical Pharmacy Conference.
Received September 11, 2023; Revised November 7, 2023; Accepted December 15, 2023.
This is an Open Access journal distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: As per guidelines for treating dyslipidemia, the recommended low-density lipoprotein cholesterol (LDL-C) level in extremely high-risk patients, including those with coronary artery diseases is <55 mg/dL. Although this recommendation has been adopted in the guidelines for dyslipidemia in various countries, there is limited evidence of its efficacy in reducing cardiovascular diseases (CVDs), especially among East Asian patients. This study aimed to investigate whether an LDL-C value below 55 mg/dL is associated with decreased risk of CVDs. Methods: Seven clinical trials including 50,970 patients that compared intensive lipidlowering therapy with less therapy or placebo in patients who had >6 months of follow-up, those with a sample size of ≥150 were selected as the final literature for analysis. Risk ratios (RR) using random effects were represented with 95% confidence intervals (CI) for the reliability of the results. Results: An LDL-C level of <55 mg/dL was related to significantly reduced events of major CVDs (RR: 0.88; 95% CI: 0.80-0.98) and myocardial infarction (RR: 0.81; 95% CI: 0.73-0.90) and a reduced risk of ischemic stroke (RR 0.79; 95% CI 0.69-0.89, mean follow-up=2 years). However, an LDL-C level below 55 mg/dL did not reduce the incidence of CVD in intensive therapy in East Asian patients. Conclusions: A goal LDL-C value below 55 mg/dL was identified to be related to a decreased risk of developing CVD. However, the relation to LDL-C below 55 mg/dL with a decreased risk of CVD was not observed in East Asian patients.
Keywords : Cardiovascular diseases, cholesterol, cholesterol-LDL

Reducing the risk of cardiovascular diseases requires effort to determine appropriate target low-density lipoprotein cholesterol (LDL-C) levels. According to the 2019 European Society of Cardiovascular/European Atherosclerosis Society guidelines for managing dyslipidemia, patients diagnosed with atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction (MI), unstable angina, and coronary revascularization, or at risk of developing ASCVD are classified as extremely high-risk patients. For such patients, LDL-C reduction by >50% or a target LDL-C level of <55 mg/dL is recommended1). The 2020 American Association of Clinical Endocrinology Clinical Practice guidelines recommend achieving LDL-C levels <55 mg/dL in diabetic patients with acute ASCVD2). In addition, the 2022 Korean Society of Lipid and Atherosclerosis dyslipidemia treatment guidelines published in November 18, 2022 recommend that patients with coronary artery disease (CAD) reduce their target LDL-C level to 55 mg/dL and by >50%3).

Setting a target LDL-C level below 55 mg/dL was based on the clinical studies, Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), ODYSSEY OUTCOMES (Effect of Alirocumab on Long-Term Cardiovascular Outcomes Following Acute Coronary Syndromes) and FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk). These clinical studies represented the significant reduction in major adverse cardiovascular events including the coronary events4-6). However, no significant reduction of cardiovascular mortality or all-cause mortality was observed despite achieving an LDL-C level of 53.7 mg/dL (hazard ratio [HR] 1.00; 95% confidence interval [95% CI], 0.89-1.13; p=1.00 and HR 0.99; 95% CI 0.91-1.07; p=0.78, respectively)4). When LDL-C levels reached 30 mg/dL with evolocumab, one of the types of PCSK9 inhibitors, insignificant reduction of cardiovascular mortality or all-cause mortality was found compared to the placebo group5). Additionally, trial participants were mainly Westerners (Caucasian), and it is difficult to determine the efficacy and safety of drug recommendations for Korean or East Asian patients, including Japanese, Chinese, Taiwanese, Hong Kongers, and Mongolians. Although a previous study compared the efficacy of evolocumab intervention for cardiovascular disease risk among Asians and non-Asians, it was limited to confirming the efficacy of the drug for cardiovascular disease or mortality in the East Asian population overall because it included Southeast Asian patients such as those from the Philippines and India.7) From the perspective of “the lower, the better” LDL-C in a dyslipidemia management strategy,8) it is essential to examine the effects of low LDL-C levels on mortality and cardiovascular disease in Korean or East Asian patients with similar characteristics. Therefore, this study aimed to investigate whether an LDL-C level of >55 mg/dL can reflect a reduced mortality rate among patients with CAD or dyslipidemia, the risk of cardiovascular diseases, and the risk of occurrence specifically in East Asian patients.

Materials and Methods

Data sources & searches

This study was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement for reporting systematic reviews as recommended by the Cochrane review.9) A comprehensive literature search was performed with language restriction including articles published in only English and Korean because of the researcher’s clear understanding of these languages. Articles were searched using electronic databases such as PubMed, EMBASE, and up to May 12, 2022. The search strategy included a combination of the following broad search terms: “lipid,” “LDL,” “cholesterol,” “statin,” “ezetimibe,” and “proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor” (Supplementary Tables 1 and 2). The study protocol for this meta-analysis was registered in the International Prospective Register for Systematic Reviews (PROSPERO) CRD42021247742 on December 13, 2022.

Selection criteria of studies

The prespecified inclusion criteria were as follows: 1) randomized controlled trials with patients with CAD or dyslipidemia using a statin only or statin plus ezetimibe, or statin plus PCSK9 inhibitors as a lipid-lowering therapy; 2) mean/median LDL-C <55 mg/dL achieved with intensive therapy; 3) follow-up period ≥6 months; and 4) sample size ≥150 patients. The exclusion criteria were as follows: 1) patients with heart failure or those requiring hemodialysis9) 2) therapy with omega 3 fatty acids10) 3) therapy with fibrates, niacin, cholesteryl ester transfer protein (CETP) inhibitors.11)

Data extraction, outcomes, and quality assessment

Two investigators (M.G.J. and Y.E.S.) independently extracted the data using prespecified criteria of data collection, evaluated the accuracy of the extraction, and resolved any discrepancies by consensus after discussion with a third investigator (K.H.S.). The extracted data included characteristics of the trial participants, crude point estimates, number of events, sample sizes, and follow-up period. Any key information related to a meta-analysis in this study but not represented in the published manuscript was also determined using Two independent investigators (M.G.J. and Y.E.S.) extracted the potential risk of bias in the trials using the Cochrane Risk of Bias Tool at the study level recommended in Cochrane Training12). The result of evaluating the risk of bias in studies is represented in Supplementary Figure 1. This study abstracted and analyzed trial-level data according to the original randomization group for which outcomes data were available. The study population was classified into 2 groups: 1) the lower LDL-C group, defined as treatment to achieve mean/median LDL-C levels <55 mg/dL with intensive lipid-lowering therapy, and 2) the higher LDL-C group, defined as treatment with less potent active control or placebo that confers higher achieved LDL-C ≥55 mg/dL. The outcomes were all-cause and cardiovascular mortality, major adverse cardiovascular events (MACE), MI, revascularization, and ischemic stroke. The meaning of MACE in each study is defined in Supplementary Table 3.

Data synthesis & analysis

Outcomes were pooled using Mantel-Haenszel random-effects model and the DerSimonian and Laird method for estimating the tau. Effect sizes are reported as risk ratios (RRs) with 95% confidence intervals (CIs). I2 statistics were used to measure the extent of unexplained statistical heterogeneity; I2 >50% was considered to indicate a high degree of statistical heterogeneity between studies.13) Publication bias was not evaluated owing to the limited number of studies reviewed because the literatures were only seven.14) To explore potential sources of heterogeneity, sensitivity and additional subgroup analysis were performed based on the type of drug (e.g., statin+ezetimibe or PCSK9 inhibitor) and population race (e.g., East Asian). Comprehensive meta-analysis was conducted using Review Manager 5.4 recommended by the Cochrane Review Groups.


Searching literatures

A total of 25,064 articles were confirmed, and duplicate documents were excluded. After excluding duplicates, 8843 articles were screened. After confirming the article titles and abstracts, 8532 articles were excluded. A total of 311 articles were full-text screened, and 304 of them were excluded for reasons such as LDL-C levels, outcome/drug ranges, heart failure or hemodialysis patients, sample size, and follow-up periods. Finally, a total of 7 articles were used for the systematic literature review and meta-analysis (Fig. 1). The risk of bias in outcomes across all studies was similar and predominately of some concern and high risk.

Fig. 1. Workflow of the selecting the literatures for systematic review and meta-analysis

Characteristics of included literatures and participants

Table 1 presents the characteristics of clinical trial participants in the seven articles analyzed. Of the seven clinical trials, two used therapies with statin and ezetimibe and five used therapies with PCSK9 inhibitors, such as evolocumab and alirocumab. The mean patient age was 64.7 years. The proportion of women was ranged 14.4%-49.5% and the mean number of female patients was about 1,935. For the lower LDL-C group (LDL-C <55 mg/dL), the average baseline LDL-C level was 112.5 mg/dL, and the average follow-up period was 2 years.

Baseline characteristics of trials and participants

Study N Age (years) N (%), Intervention Intensive therapy Placebo/less intensive therapy Follow-up (years)

Women Diabetes Active agent N LDL-C Baseline LDL-C Active agent N LDL-C
Tamio 201823) 163 63.6 20(38.7) 32(60.4) Alirocumab 53 47.4 149.2 Placebo 56 143.6 1.8
Koh 201724) 199 61.2 14(14.4) 32(33.0) Alirocumab 97 42.7 97.0 Placebo 102 102.9 0.5
Liu 201725) 219 84.0 54(47.4) 46(40.4) Statin+ezetimibe 108 46.4 85.1 Statin 111 54.1 1.0
Sabatine 20175) 27,564 62.5 6769(25.0) 10081(37.0) Evolocumab 13,784 30.0 92.0 Placebo 13,780 92.0 2.2
Tamio 201626) 216 60.3 60(41.7) 105(72.9) Alirocumab 144 53.4 143.1 Placebo 72 135.6 1.8
Cannon 20154) 18,144 63.6 4416(24.0) 4933(27.0) Statin+ezetimibe 9067 54.0 93.8 Statin 9077 70.0 6.0
Sabatine 201527) 4465 58.0 2210(49.5) 599(13.4) Evolocumab 2976 48.0 120.5 Statin 1489 121.0 0.9

Meta-analysis of outcomes

All-cause and cardiovascular mortality

Compared with the higher LDL-C group, the lower LDL-C group did not show significantly lower risks of all-cause mortality (RR 1.00; 95% CI, 0.94-1.06; p=0.93; Fig. 2) and cardiovascular mortality (RR 1.02; 95% CI, 0.92-1.13; p=0.70; Fig. 3).

Fig. 2. Effect of treatment to achieve low density lipoprotein (LDL-C, <55 mg/dL) vs higher LDL-C (≥55 mg/dL) on all-cause mortality
Fig. 3. Effect of treatment to achieve low density lipoprotein (LDL-C, <55 mg/dL) vs higher LDL-C (≥55 mg/dL) on cardiovascular mortality
Myocardial infarction, ischemic stroke, and MACE

Compared with the higher LDL-C group, the lower LDL-C group showed significantly lower risks of MI (RR 0.81; 95% CI, 0.73-0.90; p=0.0001; Supplementary Fig. 2), ischemic stroke (RR 0.79; 95% CI, 0.69-0.89; p=0.0002; Supplementary Fig. 3), and MACE (RR 0.88; 95% CI, 0.80-0.98; p=0.01; Supplementary Fig. 4).

Subgroup analysis: Race

No significant differences were observed between both groups in terms of all-cause mortality (RR 1.32; 95% CI, 0.46-3.84; p=0.61; Fig. 4), MI (RR 0.84; 95% CI, 0.40-1.80; p=0.66; Fig. 5) and MACE (RR 1.08; 95% CI 0.68-1.71; p=0.75; Fig. 6) in East Asian patients.

Fig. 4. Effect of treatment to achieve low density lipoprotein (LDL-C, <55 mg/dL) vs higher LDL-C (≥55 mg/dL) on all-cause mortality in East Asian
Fig. 5. Effect of treatment to achieve low density lipoprotein (LDL-C, <55 mg/dL) vs higher LDL-C (≥55 mg/dL) on myocardial infarction in East Asian
Fig. 6. Effect of treatment to achieve low density lipoprotein (LDL-C, <55 mg/dL) vs higher LDL-C (≥55 mg/dL) on MACE in East Asian
Sensitivity analyses and publication bias

Sensitivity analysis was performed by grouping according to drug type and race. The results were not significantly altered throughout this process.


As a result of systematic literature review and meta-analysis of this study, the mean LDL-C level achieved in patients with CAD or dyslipidemia in a mean 2-year follow-up was 102.7 mg/dL in the higher LDL-C group and 45.6 mg/dL in the lower LDL-C group. The risk of myocardial infarction, ischemic stroke, and MACE development was significantly reduced in the Low LDL-C group. However, as a result of meta-analysis of East Asian patients, including Korea, Japan, China, and Taiwan, there was no significant difference between groups in mortality and risk of cardiovascular disease.

LDL-C above a certain level is a representative cause of ASCVD, CAD, which has been repeatedly demonstrated in related previous clinical studies. The slope of the linear graph, which can confirm the association between LDL-C levels and the occurrence of ASCVD, was steep as the follow-up period increased. It can be concluded that the risk of developing ASCVD is determined by LDL-C levels throughout the patient’s lifetime.15,16) The dyslipidemia management strategy called “The lower the better” is a concept supported by clinical studies using ezetimibe and PCSK9 inhibitors based on statin.17,18) Recommendations of treatment that lower the target LDL-C levels set to reduce the risk of developing cardiovascular disease were presented based on the results of the IMPROVE-IT, FOURIER, and ODYSEEY studies.4,5,19) Based on these studies, the 2017 American Endocrinology Society presented LDL-C target levels of 55 mg/dL in patients with extreme highrisk such as CAD.20) Subsequently, the 2019 European Heart Association guidelines for dyslipidemia further recommended target LDL-C levels below 40 mg/dL for patients with a 50% reduction from existing LDL-C levels and a secondary vascular disease base within 2 years.1) However, more than 90% of the IMPROVE-IT, FOURIER, and ODYSSEY studies were white, and their efficacy for mortality was unclear.4,5,19)

According to the clinical study analyzed in this study, when LDL-C was less than 55 mg/dL, there was no significant decrease in cardiovascular disease mortality or mortality. According to a systematic literature review and meta-analysis that evaluated the validity and safety of target LDL-C levels, below of 70 mg/dL presented in the guidelines for treating dyslipidemia, there was no significant difference in mortality [RR: 0.94 (0.82, 1.08)] and cardiovascular disease mortality [RR: 0.83 (0.61, 1.14)] when compared with LDL-C 55 mg/dL or higher.10) A meta-analysis of a clinical trial study of a group of patients treated with PCSK9 inhibitors suggested that it was not associated with a decrease in mortality [Relative Risk: 0.94 (0.81, 1.09); p=0.41] regardless of LDL-C achievement levels and baseline LDL-C after follow-up.21)

Clinical studies were conducted to find appropriate LDL-C levels for the prevention of secondary occurrence in patients with CAD in East Asia, and there was no significant reduction in the risk of cardiovascular disease when less than LDL-C 55 mg/dL was achieved. As a result of analyzing 10,672 patients with myocardial infarction in Korea, the risk of developing MACE decreased after 3 years of follow-up if the achieved LDL-C level was less than 70 mg/dL and decreased by 50% or more than the base level [HR: 0.73 (0.56, 0.96); p=0.025]. However, compared with those achieved below LDL-C 55 mg/ dL and those achieved below 70 mg/dL, the risk of developing MACE after 3 years in the group below 55 mg/dL showed no significant decrease [HR: 0.75 (0.46, 1.22); p=0.247].19) A multi-center clinical study based on lipid-lowering therapy in patients of Japanese myocardial infarction suggested that the reduction in cardiovascular disease incidence was not related to the target LDL-C setting.22)

This study has the following strengths. First, when LDL-C 55 mg/dL was achieved as a target in patients with dyslipidemia, CAD, and ASCVD, overall clinical results for mortality and cardiovascular disease were identified. Second, through a subanalysis of East Asian race, it was confirmed whether the target LDL-C level of less than 55 mg/dL could be applied in the Korean patient group. However, there are also two limitations in this study. First, since the average value of the LDL-C level was confirmed as a target, it is difficult to confirm the trend in the group in which the actual LDL-C level is less than 55 mg/dL. Second, in the case of studies selected as the final literatures, there is a difference in the number of participants for each study, so it is possible that the corresponding part influenced the results. However, analysis through the classification of drug types and races solved the problem of heterogeneity that may occur between studies. Third, the number of East Asian patient groups in the literatures used in the meta-analysis of this study may have affected the results due to the small number of patients despite comprehensive literature searching procedures.


In this study, it was effective to target LDL-C levels below 55 mg/dL to lower the risk of cardiovascular disease. However, in the clinical study of East Asian patients used in systematic literature review and meta-analysis in this study, even if LDL-C levels were less than 55 mg/dL, mortality and cardiovascular disease risk were not lowered. This suggests the need for additional clinical studies aimed at less than LDL-C 55 mg/dL for East Asian patient groups.


This study was conducted with the support of the CPRN Research Council of the Korean Society of Clinical Pharmacy (KCCP20210515CPRN), and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. RS-2023-00251397).

Conflicts of Interest

The authors have no conflicts of interest to declare with regards to the contents of this study.

  1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205.
    Pubmed CrossRef
  2. Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm-2020 executive summary. Endocrr Pract. 2020;26(10):1196-224.
    Pubmed CrossRef
  3. The Korean Society of Lipid and Atherosclerosis (KSoLA) Committee of Clinical Practice Guideline. Korean guidelines for the management of dyslipidemia (the 5th edition). Available from Accessed October 01, 2022.
  4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-97.
    Pubmed CrossRef
  5. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22.
    Pubmed CrossRef
  6. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097-107.
    Pubmed CrossRef
  7. Keech AC, Oyama K, Sever PS, et al. Efficacy and safety of longterm evolocumab use among Asian subjects - a subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Circ J. 2021;85(11):2063-70.
    Pubmed CrossRef
  8. Martin SS, Blumenthal RS, Miller M. LDL cholesterol: the lower the better. Med Clin North Am. 2012;96(1):13-26.
    Pubmed CrossRef
  9. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and metaanalysis. JAMA. 2018;319(15):1566-79.
    Pubmed KoreaMed CrossRef
  10. Khan SU, Khan MU, Virani SS, et al. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and metaanalysis. Eur J Prev Cardiol. 2021;28(18):2001-9.
    Pubmed CrossRef
  11. Riaz H, Khan SU, Rahman H, et al. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2019;26(5):533-43.
    Pubmed KoreaMed CrossRef
  12. Cochrane. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 2023. Available from Accessed October 01, 2022.
  13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
    Pubmed KoreaMed CrossRef
  14. Nam JH, Kim CY, Lee YK, Jung DW, Gwak HY, Chung JE. Apixaban versus warfarin in patients with chronic kidney disease; a systematic review and Meta-analysis. KJCP. 2021;31(2):87-95.
  15. Penson PE, Pirro M, Banach M. LDL-C: lower is better for longereven at low risk. BMC Med. 2020;18(1):1-6.
    Pubmed KoreaMed CrossRef
  16. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72.
    Pubmed KoreaMed CrossRef
  17. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438-45.
    Pubmed CrossRef
  18. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-65.
    Pubmed CrossRef
  19. Ahn JH, Ahn Y, Jeong MH, et al. Optimal low-density lipoprotein cholesterol target level in Korean acute myocardial infarction patients (<70 mg/dL vs. <55 mg/dL): based on Korea acute myocardial infarction registry-National Institute of Health. Int J Cardiol. 2022;351:15-22.
    Pubmed CrossRef
  20. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1-87.
  21. Khan SU, Riaz H, Rahman H, et al. Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: a systematic review and meta-analysis. J Clin Lipidol. 2019;13(4):538-49.
    Pubmed KoreaMed CrossRef
  22. Sakamoto T, Ogawa H. "Just make it lower" is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: LDL-cholesterol: the lower, the better; is it true for Asians? (Con). Circ J. 2010;74(8):1731-41.
    Pubmed CrossRef
  23. Teramoto T, Kiyosue A, Ishigaki Y, et al. Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON. J Cardiol. 2019;73(3):218-27.
    Pubmed CrossRef
  24. Koh KK, Nam CW, Chao TH, et al. A randomized trial evaluating the efficacy and safety of alirocumab in south korea and taiwan (ODYSSEY-KT). J Clin Lipidol. 2018;12(1):162-72.
    Pubmed CrossRef
  25. Liu Z, Hao H, Yin C, Chu Y, Li J, Xu D. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Oncotarget. 2017;8(25):41582-9.
    Pubmed KoreaMed CrossRef
  26. Teramoto, Tamio, et al. Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins - ODYSSEY JAPAN randomized controlled trial. Cir J. 2016;80(9):1980-7.
    Pubmed CrossRef
  27. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-9.
    Pubmed CrossRef

March 2024, 34 (1)
Full Text(PDF) Free

Social Network Service

Cited By Articles
  • CrossRef (0)